Josep M Llovet Bayer

Josep M Llovet Bayer

Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer

Life & Medical Sciences

Josep M Llovet, MD, PhD is ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the Univ.Barcelona. Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). He has published 359 manuscripts (scopus citations:112,377; h-index:134; IF:8,590). Top 1% most cited researcher globally by Clarivate Analytics (2014-23), and world most cited investigator in liver cancer. Major achievements: a) Defining molecular and immune classes of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), b) discovery of drivers as therapeutic targets in liver cancer, and c) Establishing standard therapies for HCC, such as sorafenib, regorafenib, ramucirumab and chemoembolization. He is Editor-in-Chief of J HEP Reports, Founder and President of ILCA (2006-13), delivered > 700 lectures, and PI of ~100 competitive grants [coordinator of 2 European FP7 & Horizon Europe grants and 2 NIH-RO1].

Research interests

Prof Josep M. Llovet research has been focused on clinical and translational studies in liver cancer for the last 30 years. He is leading international randomized trials on immunotherapies and European and international consortiums for liver cancer research assessing molecular mechanism of response to immunotherapies. His main areas of interest are a) characterize the human atlas of immune populations in liver cancer b) identify mechanisms and biomarkers predicting response and resistance to checkpoint inhibitors for hepatocellular carcinoma (HCC) through single-cell data and spatial transcriptomics, NGS and artificial intelligence; c) translate oncogenic drivers discoveries as targeted therapies in liver cancer, d) exploring the role of liver microbiome in the pathogenesis of HCC. e) identification of drugs which, when combined, have synergistic effects; f) improving knowledge about the mechanisms involved in the origin, progression and dissemination of MASH-HCC

Selected publications

- Montironi C, Castet F, Haber P....Llovet JM. 2023 'Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification' , Gut. 72:129-140.
- Haber PK, Castet F, Torres-Martin M ... Llovet JM. 2023, 'Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma', Gastroenterology, 164:72-88
- Singal AG, Kanwal F & Llovet JM 2023, 'Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy', Nature Reviews Clinical Oncology, 20:864-884.
- Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS & Friedman SL. 2023, 'Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment', Nature Reviews Gastroenterology & Hepatology, 20:487-503
- Singal, AG, Llovet JM, Yarchoan M et al. 2023, ‘AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinomaHepatology, 78:1922-1965.